GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » EV-to-Revenue

CHMMF (Chimeric Therapeutics) EV-to-Revenue : (As of May. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Chimeric Therapeutics's enterprise value is $5.55 Mil. Chimeric Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Chimeric Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Chimeric Therapeutics's EV-to-Revenue or its related term are showing as below:

CHMMF's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.42
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-30), Chimeric Therapeutics's stock price is $0.001. Chimeric Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Therefore, Chimeric Therapeutics's PS Ratio for today is .


Chimeric Therapeutics EV-to-Revenue Historical Data

The historical data trend for Chimeric Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics EV-to-Revenue Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
EV-to-Revenue
- - - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Chimeric Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Chimeric Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimeric Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's EV-to-Revenue falls into.


;
;

Chimeric Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Chimeric Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5.545/0
=

Chimeric Therapeutics's current Enterprise Value is $5.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics  (OTCPK:CHMMF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Chimeric Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.001/0
=

Chimeric Therapeutics's share price for today is $0.001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimeric Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research 02-13-2024